Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential predictive value of resident memory CD8+T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy.
Paolini L, Tran T, Corgnac S, Villemin JP, Wislez M, Arrondeau J, Johannes L, Ulmer J, Vieillard LV, Pineau J, Gey A, Quiniou V, Barennes P, Pham HP, Gruel N, Hasan M, Libri V, Mella S, De Percin S, Boudou-Rouquette P, Caidi A, Cremer I, Blons H, Leroy K, Laurent-Puig P, De Saint Basile H, Gibault L, Ravel P, Mami-Chouaib F, Goldwasser F, Fabre E, Damotte D, Tartour E. Paolini L, et al. Among authors: goldwasser f. J Immunother Cancer. 2024 Dec 3;12(12):e009440. doi: 10.1136/jitc-2024-009440. J Immunother Cancer. 2024. PMID: 39631852 Free PMC article.
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.
Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B. Puszkiel A, et al. Among authors: goldwasser f. J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24. J Pharm Biomed Anal. 2017. PMID: 28260630
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. Biton J, et al. Among authors: goldwasser f. Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15. Clin Cancer Res. 2018. PMID: 29764856
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.
Jouinot A, Ulmann G, Vazeille C, Durand JP, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Fournel L, Alifano M, Wislez M, Chapron J, Le Bris C, Mansuet-Lupo A, Damotte D, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F. Jouinot A, et al. Among authors: goldwasser f. Clin Nutr. 2020 Jun;39(6):1893-1899. doi: 10.1016/j.clnu.2019.08.003. Epub 2019 Aug 10. Clin Nutr. 2020. PMID: 31443979
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: goldwasser f. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Fournel L, et al. Among authors: goldwasser f. Cancer Chemother Pharmacol. 2020 Oct;86(4):497-505. doi: 10.1007/s00280-020-04142-9. Epub 2020 Sep 16. Cancer Chemother Pharmacol. 2020. PMID: 32936316
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Boudou-Rouquette P, et al. Among authors: goldwasser f. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688030 Free PMC article.
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-Rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-Lupo A. Velut Y, et al. Among authors: goldwasser f. Lung Cancer. 2022 Jul;169:13-21. doi: 10.1016/j.lungcan.2022.05.001. Epub 2022 May 5. Lung Cancer. 2022. PMID: 35597058
Predictive factors associated with pemetrexed acute toxicity.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, Vidal M, Batista R, Wislez M, Blanchet B, Goldwasser F, Thomas-Schoemann A. Bonnet M, et al. Among authors: goldwasser f. Eur J Clin Pharmacol. 2023 May;79(5):635-641. doi: 10.1007/s00228-023-03478-4. Epub 2023 Mar 23. Eur J Clin Pharmacol. 2023. PMID: 36951965
340 results